Background
Endothelial Cell Differentiation Gene-7 (EDG7) (LPA3) belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG-7 is lysophospholipid. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. They couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C and several protein tyrosine kinases. EDG7 (LPA3) is expressed in prostate as well as other tissues.

Synonyms: Blocking peptide for use in Western blotting with Anti-EDG7 (LPA3) (CT) (Cat. No. X1183P)

Product

Product Form: Unconjugated

Formulation: Provided in solution at 1 mg/ml in phosphate buffered saline.

Concentration: See vial for concentration

Applications
For use with EDG7 (LPA3) (CT) polyclonal antibody (Cat. No. X1183P).

Functional Analysis: Western Blotting

Storage
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.